Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) is 4.58% higher on its value in year-to-date trading and has touched a low of $0.92 and a high of $3.73 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LXRX stock was last observed hovering at around $1.54 in the last trading session, with the day’s gains setting it 0.06%.
Currently trading at $1.60, the stock is -2.56% and -10.15% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.81 million and changing 3.90% at the moment leaves the stock -14.28% off its SMA200. LXRX registered 32.23% gain for a year compared to 6-month loss of -33.33%. The firm has a 50-day simple moving average (SMA 50) of $1.7712 and a 200-day simple moving average (SMA200) of $1.8685.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -6.98% gain in the last 1 month and extending the period to 3 months gives it a -4.76%, and is -3.61% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.07% over the week and 5.62% over the month.
Lexicon Pharmaceuticals Inc (LXRX) has around 285 employees, a market worth around $578.38M and $3.64M in sales. Profit margin for the company is -5509.34%. Distance from 52-week low is 73.91% and -57.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.25%).
with sales reaching $5.22M over the same period.The EPS is expected to grow by 14.47% this year, but quarterly earnings will post 1,261.30% year-over-year. Quarterly sales are estimated to grow 3,122.20% in year-over-year returns.
Lexicon Pharmaceuticals Inc (LXRX) Top Institutional Holders
172.0 institutions hold shares in Lexicon Pharmaceuticals Inc (LXRX), with institutional investors hold 80.16% of the company’s shares. The shares outstanding are 361.49M, and float is at 349.07M with Short Float at 7.63%. Institutions hold 79.24% of the Float.
The top institutional shareholder in the company is ARTAL GROUP S.A. with over 175.1 million shares valued at $294.17 million. The investor’s holdings represent 71.3555% of the LXRX Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 38.69 million shares valued at $64.99 million to account for 15.7656 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 9.89 million shares representing 4.0304% and valued at over $16.62 million, while BRAIDWELL LP holds 3.3803 of the shares totaling 8.29 million with a market value of $13.94 million.
Lexicon Pharmaceuticals Inc (LXRX) Insider Activity
#####
Lexicon Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 16 ’23 that COATS LONNEL (Chief Executive Officer) bought a total of 90,000 shares of the company’s common stock. The trade occurred on Nov 16 ’23 and was made at $1.05 per share for $94797.0. Following the transaction, the insider now directly holds 0.91 million shares of the LXRX stock.
Still, SEC filings show that on Nov 10 ’23, COATS LONNEL (Chief Executive Officer) acquired 10,000 shares at an average price of $1.01 for $10100.0. The insider now directly holds 824,359 shares of Lexicon Pharmaceuticals Inc (LXRX).